Parasitic diseases in travelers: a focus on therapy

References

• Boggild A, Yohanna S, Keystone JS, Kain KC. Prospective analysis of parasitic infections in Canadian travelers and immigrants. J Travel Med 2006;13(3):138-44
   PubMed Web of Science ®Google Scholar
• Leder K, Torresi J, Libman M. GeoSentinel surveillance of illness in returned travelers, 2007-2011. Ann Intern Med 2013;158(6):456-68
   PubMed Web of Science ®Google Scholar
• Jensenius M, Han PV, Schlagenhauf P, et al. Acute and potentially life-threatening tropical diseases in western travelers–a GeoSentinel multicenter study. 1996–2011.Am J Trop Med Hyg 2013;88(2):397-404
   Google Scholar
• Wilson ME, Freedman DO. Etiology of travel-related fever. Curr Opin Infect Dis 2007;20(5):449-53
   PubMed Web of Science ®Google Scholar
• Wilson ME, Weld LH, Boggild AK, et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007;44:1560-8
   PubMed Web of Science ®Google Scholar
• Baas MC, Wetsteyn JCFM, van Gool T. Patterns of imported malaria at the academic medical center, Amsterdam, the Netherlands. J Travel Med 2006;13(1):2-7
   PubMed Web of Science ®Google Scholar
• Bottieau E, Clerinx J, Van Den Enden E, et al. Imported non-Plasmodium falciparum malaria: a five-year prospective study in a European referral center. Am J Trop Med Hyg 2006;75(1):133-8
   PubMed Web of Science ®Google Scholar
• Rosenblatt JE. Laboratory diagnosis of infections due to blood and tissue parasites. Clin Infect Dis 2009;49(7):1103-8
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the treatment of malaria. 2nd edition. World Health Organization; Geneva, Switzerland: 2010
   Google Scholar
• Dondorp AM, Fanello CI, Hendriksen ICE, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010;376(9753):1647-57
   PubMed Web of Science ®Google Scholar
• Dondorp A, Nosten F, Stepniewska K, et al., South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005;366(9487):717-25
   PubMed Web of Science ®Google Scholar
• Sinclair D, Donegan S, Isba R, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev 2012;6:CD005967
   Google Scholar
• Van Genderen PJJ, Hesselink DA, Bezemer JM, et al. Efficacy and safety of exchange transfusion as an adjunct therapy for severe Plasmodium falciparum malaria in nonimmune travelers: a 10-year single-center experience with a standardized treatment protocol. Transfusion 2010;50(4):787-94
   PubMed Web of Science ®Google Scholar
• Tan KR, Wiegand RE, Arguin PM. Exchange transfusion for severe malaria: evidence base and literature review. Clin Infect Dis 2013;57(7):923-8
   PubMed Web of Science ®Google Scholar
• CDC. Treatment of Malaria (Guidelines For Clinicians). CDC; Atlanta, USA: 2013
   Google Scholar
• Daneshvar C, Davis TME, Cox-Singh J, et al. Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. Malar J 2010;9:238
   PubMed Web of Science ®Google Scholar
• Kantele A, Jokiranta TS. Review of cases with the emerging fifth human malaria parasite, Plasmodium knowlesi. Clin Infect Dis 2011;52(11):1356-62
   PubMed Web of Science ®Google Scholar
• Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012;379(9830):1960-6
   PubMed Web of Science ®Google Scholar
• White NJ, Pukrittayakamee S, Hien TT, et al. Malaria. Lancet 2013. [Epub ahead of print]
   Google Scholar
• Kyaw MP, Nyunt MH, Chit K, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in Southern Myanmar. Borrmann S, ed. PLoS One 2013;8(3):e57689
   PubMed Web of Science ®Google Scholar
• Maguire JD, Sumawinata IW, Masbar S, et al. Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet 2002;360(9326):58-60
   PubMed Web of Science ®Google Scholar
• Tyagi RK, Das MK, Singh SS, Sharma YD. Discordance in drug resistance-associated mutation patterns in marker genes of Plasmodium falciparum and Plasmodium knowlesi during coinfections. J Antimicrob Chemother 2013;68(5):1081-8
   PubMed Web of Science ®Google Scholar
• William T, Menon J, Rajahram G, et al. Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerg Infect Dis 2011;17(7):1248-55
   PubMed Web of Science ®Google Scholar
• Barber BE, William T, Grigg MJ, et al. A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis 2013;56(3):383-97
   PubMed Web of Science ®Google Scholar
• Mäser P, Wittlin S, Rottmann M, et al. Antiparasitic agents: new drugs on the horizon. Curr Opin Pharmacol 2012;12(5):562-6
   PubMed Web of Science ®Google Scholar
• Charman SA, Arbe-Barnes S, Bathurst IC, et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci USA 2011;108(11):4400-5
   PubMed Web of Science ®Google Scholar
• Medicines for Malaria Venture. Interactive R&D portfolio. Available from: www.mmv.org/research-development/rd-portfolio [Accessed 23 September 2013]
   Google Scholar
• Spillman NJ, Allen RJW, McNamara CW, et al. Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe 2013;13(2):227-37
   PubMed Web of Science ®Google Scholar
• Rottmann M, Mcnamara C, Yeung BKS, et al. Spiroindolones, a new and potent chemotype for the treatment of malaria. Science 2010;329(5996):1175-80
   PubMed Web of Science ®Google Scholar
• Nilsen A, LaCrue AN, White KL, et al. Quinolone-3-diarylethers: a new class of antimalarial drug. Sci Transl Med 2013;5(177):177ra37
   PubMed Web of Science ®Google Scholar
• Suzuki S. Priority Medicines for Europe and the World “A Public Health Approach to Innovation” Update on 2004 Background Paper, BP 6.10 Malaria. World Health Organization, Geneva, Switzerland; 2013. Available from: http://www.who.int/medicines/areas/priority_medicines/en/
   Google Scholar
• Haque R, Kabir M, Noor Z, et al. Diagnosis of amebic liver abscess and amebic colitis by detection of Entamoeba histolytica DNA in blood, urine, and saliva by a real-time PCR assay. J Clin Microbiol 2010;48(8):2798-801
   PubMed Web of Science ®Google Scholar
• Davila-Gutierrez CE, Vasquez C, Trujillo-Hernandez B, Huerta M. Nitazoxanide compared with quinfamide and mebendazole in the treatment of helminthic infections and intestinal protozoa in children. Am J Trop Med Hyg 2002;66(3):251-4
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001;184(3):381-4
   PubMed Web of Science ®Google Scholar
• Rossignol J-F, Kabil SM, El-Gohary Y, Younis AM. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg 2007;101(10):1025-31
   PubMed Web of Science ®Google Scholar
• Ali V, Nozaki T. Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by “amitochondriate” protozoan parasites. Clin Microbiol Rev 2007;20(1):164-87
   PubMed Web of Science ®Google Scholar
• Kain KC, Boggild AK. Amebiasis. In: Rakel RE, Bope ET, editors. Conn’s current therapy. 56th edition. WB Saunders Co; 2004. p. 60-3
   Google Scholar
• Bammigatti C, Ramasubramanian NS, Kadhiravan T, Das AK. Percutaneous needle aspiration in uncomplicated amebic liver abscess: a randomized trial. Trop Doct 2013;43(1):19-22
   PubMed Web of Science ®Google Scholar
• Chavez-Tapia NC, Hernandez-Calleros J, Tellez-Avila FI, et al. Image-guided percutaneous procedure plus metronidazole versus metronidazole alone for uncomplicated amoebic liver abscess. Cochrane Database Syst Rev 2009(1):CD004886
   PubMed Web of Science ®Google Scholar
• Lim P-L, Han P, Chen LH, et al. Expatriates ill after travel: results from the Geosentinel Surveillance Network. BMC Infect Dis 2012;12:386
   PubMed Web of Science ®Google Scholar
• Chen LH, Wilson ME, Davis X, et al. Illness in long-term travelers visiting GeoSentinel clinics. Emerg Infect Dis 2009;15(11):1773-82
   PubMed Web of Science ®Google Scholar
• Grobusch MP, Mühlberger N, Jelinek T, et al. Imported schistosomiasis in Europe: sentinel surveillance data from TropNetEurop. J Travel Med 2003;10(3):164-9
   PubMed Web of Science ®Google Scholar
• Bottieau E, Clerinx J, de Vega MR, et al. Imported Katayama fever: clinical and biological features at presentation and during treatment. J Infect 2006;52(5):339-45
   PubMed Web of Science ®Google Scholar
• Bottieau E, Clerinx J, Schrooten W, et al. Etiology and outcome of fever after a stay in the tropics. Arch Intern Med 2006;166(15):1642-8
   PubMedGoogle Scholar
• Schulte C, Krebs B, Jelinek T, et al. Diagnostic significance of blood eosinophilia in returning travelers. Clin Infect Dis 2002;34(3):407-11
   PubMed Web of Science ®Google Scholar
• Whitty CJ, Mabey DC, Armstrong M, et al. Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a non-endemic country. Trans R Soc Trop Med Hyg 2000;94(5):531-4
   PubMed Web of Science ®Google Scholar
• Wichmann D, Poppert S, Von Thien H, et al. Prospective European-wide multicentre study on a blood based real-time PCR for the diagnosis of acute schistosomiasis. BMC Infect Dis 2013;13(1):55
   PubMedGoogle Scholar
• Yong MK, Beckett CL, Leder K, et al. Long-term follow-up of schistosomiasis serology post-treatment in Australian travelers and immigrants. J Travel Med 2010;17(2):89-93
   PubMed Web of Science ®Google Scholar
• Pérez del Villar L, Burguillo FJ, López-Abán J, Muro A. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS One 2012;7(9):e45867
   PubMed Web of Science ®Google Scholar
• Li Y-S, Chen H-G, He H-B, et al. A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China. Acta Trop 2005;96(2-3):184-90
   PubMed Web of Science ®Google Scholar
• Keiser J, N’Guessan NA, Adoubryn KD, et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis 2010;50(9):1205-13
   PubMed Web of Science ®Google Scholar
• Basra A, Mombo-Ngoma G, Capan Melser M, et al. Efficacy of Mefloquine Intermittent Preventive Treatment in Pregnancy Against Schistosoma haematobium Infection in Gabon: a Nested Randomized Controlled Assessor-Blinded Clinical Trial. Clin Infect Dis 2012;56(6):e68-75
   PubMed Web of Science ®Google Scholar
• Sayed AA, Simeonov A, Thomas CJ, et al. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 2008;14(4):407-12
   PubMed Web of Science ®Google Scholar
• Simarro PP, Franco JR, Cecchi G, et al. Human African trypanosomiasis in non-endemic countries (2000–2010). J Travel Med 2012;19(1):44-53
   PubMed Web of Science ®Google Scholar
• Pepin J, Milord F, Guern C, et al. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet 1989;1(8649):1246-50
   PubMed Web of Science ®Google Scholar
• Lutje V, Seixas J, Kennedy A. Chemotherapy for second-stage human African trypanosomiasis. Cochrane Database Syst Rev 2013;6:CD006201
   Google Scholar
• Bisser S, N’Siesi F-X, Lejon V, et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 2007;195(3):322-9
   PubMed Web of Science ®Google Scholar
• Babokhov P, Sanyaolu AO, Oyibo WA, et al. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis. Pathog Glob Health 2013;107(5):242-52
   PubMed Web of Science ®Google Scholar
• Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009;374(9683):56-64
   PubMed Web of Science ®Google Scholar
• Drugs for Neglected Disease initiative. Fexinidazole (HAT). 2013. Available from: http://www.dndi.org/diseases-projects/portfolio/fexinidazole.html [Last accessed 23 September 2013]
   Google Scholar
• Jacobs RT, Nare B, Wring SA, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis 2011;5(6):e1151
   PubMed Web of Science ®Google Scholar
• Drugs for Neglected Disease initiative. Oxaborole SCYX-7158 (HAT). 2013. Available from: http://www.dndi.org/diseases-projects/portfolio/oxaborole-scyx-7158.html Last accessed 23 September 2013]
   Google Scholar
• Rodgers J, Jones A, Gibaud S, et al. Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis. PLoS Negl Trop Dis 2011;5(9):e1308
   PubMed Web of Science ®Google Scholar
• Slom TJ, Cortese MM, Gerber SI, et al. An outbreak of eosinophilic meningitis caused by Angiostrongylus cantonensis in travelers returning from the Caribbean. N Engl J Med 2002;346(9):668-75
   PubMed Web of Science ®Google Scholar
• Malvy D, Ezzedine K, Receveur M-C, et al. Cluster of eosinophilic meningitis attributable to Angiostrongylus cantonensis infection in French policemen troop returning from the Pacific Islands. Travel Med Infect Dis 2008;6(5):301-4
   PubMedGoogle Scholar
• Chotmongkol V, Kittimongkolma S, Niwattayakul K, et al. Comparison of prednisolone plus albendazole with prednisolone alone for treatment of patients with eosinophilic meningitis. Am J Trop Med Hyg 2009;81(3):443-5
   PubMed Web of Science ®Google Scholar
• Jitpimolmard S, Sawanyawisuth K, Morakote N, et al. Albendazole therapy for eosinophilic meningitis caused by Angiostrongylus cantonensis. Parasitol Res 2007;100(6):1293-6
   PubMed Web of Science ®Google Scholar
• Thanaviratananich S, Thanaviratananich S, Ngamjarus C. Corticosteroids for parasitic eosinophilic meningitis. Cochrane Database Syst Rev 2012;10:CD009088
   PubMedGoogle Scholar
• Katchanov J, Sawanyawisuth K, Chotmongkoi V, Nawa Y. Neurognathostomiasis, a neglected parasitosis of the central nervous system. Emerg Infect Dis 2011;17(7):1174-80
   PubMed Web of Science ®Google Scholar
• Kraivichian K, Nuchprayoon S, Sitichalernchai P, et al. Treatment of cutaneous gnathostomiasis with ivermectin. Am J Trop Med Hyg 2004;71(5):623-8
   PubMed Web of Science ®Google Scholar
• Bussaratid V, Desakorn V, Krudsood S, et al. Efficacy of ivermectin treatment of cutaneous gnathostomiasis evaluated by placebo-controlled trial. Southeast Asian J Trop Med Public Health 2006;37(3):433-40
   PubMedGoogle Scholar
• Kraivichian P, Kulkumthorn M, Yingyourd P, et al. Albendazole for the treatment of human gnathostomiasis. Trans R Soc Trop Med Hyg 1992;86(4):418-21
   PubMed Web of Science ®Google Scholar
• Nontasut P, Bussaratid V, Chullawichit S, et al. Comparison of ivermectin and albendazole treatment for gnathostomiasis. Southeast Asian J Trop Med Public Health 2000;31(2):374-7
   PubMedGoogle Scholar
• Moore DAJ, McCroddan J, Dekumyoy P, Chiodini PL. Gnathostomiasis: an emerging imported disease. Emerg Infect Dis 2003;9(6):647-50
   PubMed Web of Science ®Google Scholar
• Marti H, Haji HJ, Savioli L, et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 1996;55(5):477-81
   PubMed Web of Science ®Google Scholar
• Gann PH, Neva FA, Gam AA. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 1994;169(5):1076-9
   PubMed Web of Science ®Google Scholar
• Suputtamongkol Y, Premasathian N, Bhumimuang K, et al. Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. PLoS Negl Trop Dis 2011;5(5):e1044
   PubMed Web of Science ®Google Scholar
• Juan JO, Lopez Chegne N, Gargala G, Favennec L. Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru. Trans R Soc Trop Med Hyg 2002;96(2):193-6
   PubMed Web of Science ®Google Scholar
• Belizario VY, Amarillo ME, de Leon WU, et al. A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. Bull World Health Organ 2003;81(1):35-42
   PubMed Web of Science ®Google Scholar
• Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 2008;299(16):1937-48
   PubMed Web of Science ®Google Scholar
• Flohr C, Tuyen LN, Lewis S, et al. Low efficacy of mebendazole against hookworm in Vietnam: two randomized controlled trials. Am J Trop Med Hyg 2007;76(4):732-6
   PubMed Web of Science ®Google Scholar
• Lipner EM, Law MA, Barnett E, et al. Filariasis in travelers presenting to the GeoSentinel Surveillance Network. PLoS Negl Trop Dis 2007;1(3):e88
   PubMed Web of Science ®Google Scholar
• Norman FF, Pérez de Ayala A, Pérez-Molina J-A, et al. Neglected tropical diseases outside the tropics. PLoS Negl Trop Dis 2010;4(7):e762
   PubMed Web of Science ®Google Scholar
• Antinori S, Schifanella L, Million M, et al. Imported Loa loa filariasis: three cases and a review of cases reported in non-endemic countries in the past 25 years. Int J Infect Dis 2012;16(9):e649-62
   PubMed Web of Science ®Google Scholar
• Fink DL, Kamgno J, Nutman TB. Rapid molecular assays for specific detection and quantitation of Loa loa microfilaremia. PLoS Negl Trop Dis 2011;5(8):e1299
   PubMed Web of Science ®Google Scholar
• Turner JD, Tendongfor N, Esum M, et al. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa Co-Endemicity: A randomized controlled trial. Lammie PJ, ed. PLoS Negl Trop Dis 2010;4(4):e660
   PubMed Web of Science ®Google Scholar
• Babalola OE. Ocular onchocerciasis: current management and future prospects. Clin Ophthalmol 2011;5:1479-91
   PubMedGoogle Scholar
• TDR. Research profile of moxidectin at TDR. Available from: www.who.int/tdr/research/ntd/onchocerciasis/moxidectin_research_profiles/en/index.html [Last accessed 5 October 2013]
   Google Scholar
• Bygott JM, Chiodini PL. Praziquantel: neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease? Acta Trop 2009;111(2):95-101
   PubMed Web of Science ®Google Scholar
• Keshmiri M, Baharvahdat H, Fattahi SH, et al. Albendazole versus placebo in treatment of echinococcosis. Trans R Soc Trop Med Hyg 2001;95(2):190-4
   PubMed Web of Science ®Google Scholar
• Keshmiri M, Baharvahdat H, Fattahi SH, et al. A placebo controlled study of albendazole in the treatment of pulmonary echinococcosis. Eur Respir J 1999;14(3):503-7
   PubMed Web of Science ®Google Scholar
• Bildik N, Cevik A, Altintaş M, et al. Efficacy of preoperative albendazole use according to months in hydatid cyst of the liver. J Clin Gastroenterol 2007;41(3):312-16
   PubMed Web of Science ®Google Scholar
• Brunetti E, Kern P, Vuitton DA; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010;114(1):1-16
   PubMed Web of Science ®Google Scholar
• Stojkovic M, Zwahlen M, Teggi A, et al. Treatment response of cystic echinococcosis to benzimidazoles: a systematic review. Carabin H, ed. PLoS Negl Trop Dis 2009;3(9):e524
   PubMed Web of Science ®Google Scholar
• Smego RA Jr, Bhatti S, Khaliq AA, Beg MA. Percutaneous aspiration-injection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis. Clin Infect Dis 2003;37(8):1073-83
   PubMed Web of Science ®Google Scholar
• Neumayr A, Troia G, de Bernardis C, et al. Justified concern or exaggerated fear: the risk of anaphylaxis in percutaneous treatment of cystic echinococcosis-a systematic literature review. Brooker S, ed. PLoS Negl Trop Dis 2011;5(6):e1154
   PubMed Web of Science ®Google Scholar
• Esposito DH, Freedman DO, Neumayr A, Parola P. Ongoing outbreak of an acute muscular Sarcocystis-like illness among travellers returning from Tioman Island, Malaysia, 2011–2012. Euro Surveill 2012;17:45
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Notes from the field: acute muscular sarcocystosis among returning travelers - Tioman Island, Malaysia, 2011. MMWR Morb Mortal Wkly Rep 2012;61(2):37-8
   PubMedGoogle Scholar
• Leshem E, Kliers I, Bakon M, et al. Neurocysticercosis in travelers: a nation-wide study in Israel. J Travel Med 2011;18(3):191-7
   PubMed Web of Science ®Google Scholar
• Abba K, Ramaratnam S, Ranganathan LN. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev 2010(3):CD000215
   Web of Science ®Google Scholar
• Carpio A, Kelvin EA, Bagiella E, et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008;79(9):1050-5
   PubMed Web of Science ®Google Scholar
• Del Brutto OH, Roos KL, Coffey CS, García HH. Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 2006;145(1):43-51
   PubMed Web of Science ®Google Scholar
• Garcia HH, Pretell EJ, Gilman RH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004;350(3):249-58
   PubMed Web of Science ®Google Scholar
• Baird RA, Wiebe S, Zunt JR, et al. Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the guideline development subcommittee of the American academy of neurology. Neurology 2013;80(15):1424-9
   PubMed Web of Science ®Google Scholar
• Otte WM, Singla M, Sander JW, Singh G. Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis. Neurology 2013;80(2):152-62
   PubMed Web of Science ®Google Scholar
• Gottstein B, Pozio E, Nockler K. Epidemiology, diagnosis, treatment, and control of trichinellosis. Clin Microbiol Rev 2009;22(1):127-45
   PubMed Web of Science ®Google Scholar
• Watt G, Saisorn S, Jongsakul K, et al. Blinded, placebo-controlled trial of antiparasitic drugs for trichinosis myositis. J Infect Dis 2000;182(1):371-4
   PubMed Web of Science ®Google Scholar
• Talaie H, Emami H, Yadegarinia D, et al. Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis. Clin Exp Pharmacol Physiol 2004;31(11):777-82
   PubMed Web of Science ®Google Scholar
• Favennec L, Jave Ortiz J, Gargala G, et al. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther 2003;17(2):265-70
   PubMed Web of Science ®Google Scholar
• Hien TT, Truong NT, Minh NH, et al. A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam. Am J Trop Med Hyg 2008;78(3):388-92
   PubMed Web of Science ®Google Scholar
• Ryan ET, Wilson ME, Kain KC. Illness after international travel. N Engl J Med 2002;347(7):505-16
   PubMed Web of Science ®Google Scholar
• Okhuysen PC. Traveler’s diarrhea due to intestinal protozoa. Clin Infect Dis 2001;33(1):110-14
   PubMed Web of Science ®Google Scholar
• Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006;354(2):119-30
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Hidalgo H, Feregrino M, et al. A double-’blind’ placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 1998;92(6):663-6
   PubMed Web of Science ®Google Scholar
• Rossignol J-F, Kabil SM, el-Gohary Y, Younis AM. Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. Clin Gastroenterol Hepatol 2006;4(3):320-4
   PubMed Web of Science ®Google Scholar
• Hoge CW, Shlim DR, Ghimire M, et al. Placebo-controlled trial of co-trimoxazole for Cyclospora infections among travellers and foreign residents in Nepal. Lancet 1995;345(8951):691-3
   PubMed Web of Science ®Google Scholar
• Verdier RI, Fitzgerald DW, Johnson WD Jr, Pape JW. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med 2000;132(11):885-8
   PubMed Web of Science ®Google Scholar
• Granados CE, Reveiz L, Uribe LG, Criollo CP. Drugs for treating giardiasis. In: The Cochrane Collaboration, Granados CE, editors. Cochrane database of systematic reviews. John Wiley & Sons, Ltd; Chichester, UK: 2012. Available from: http://doi.wiley.com/10.1002/14651858.CD007787.pub2 [Last accessed 22 September 2013]
   Google Scholar
• Solaymani-Mohammadi S, Genkinger JM, Loffredo CA, Singer SM. A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis. PLoS Negl Trop Dis 2010;4(5):e682
   PubMed Web of Science ®Google Scholar
• Cañete R, Escobedo AA, González ME, et al. A randomized, controlled, open-label trial of a single day of mebendazole versus a single dose of tinidazole in the treatment of giardiasis in children. Curr Med Res Opin 2006;22(11):2131-6
   PubMed Web of Science ®Google Scholar
• Escobedo AA, Alvarez G, González ME, et al. The treatment of giardiasis in children: single-dose tinidazole compared with 3 days of nitazoxanide. Ann Trop Med Parasitol 2008;102(3):199-207
   PubMed Web of Science ®Google Scholar
• Upcroft JA, Campbell RW, Benakli K, et al. Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and -resistant Giardia, Trichomonas, and Entamoeba spp. Antimicrob Agents Chemother 1999;43(1):73-6
   PubMed Web of Science ®Google Scholar
• Upcroft JA, Upcroft P. Drug resistance and Giardia. Parasitol Today (Regul Ed) 1993;9(5):187-90
   PubMedGoogle Scholar
• Upcroft J, Mitchell R, Chen N, Upcroft P. Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in beta-tubulin. Microb Drug Resist 1996;2(3):303-8
   PubMed Web of Science ®Google Scholar
• Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 2001;14(1):150-64
   PubMed Web of Science ®Google Scholar
• Swaminathan A, Torresi J, Schlagenhauf P, et al. A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. J Infect 2009;59:19-27
   PubMed Web of Science ®Google Scholar
• Adams VJ, Lombard CJ, Dhansay MA, et al. Efficacy of albendazole against the whipworm trichuris trichiura–a randomised, controlled trial. S Afr Med J 2004;94(12):972-6
   PubMed Web of Science ®Google Scholar
• Knopp S, Mohammed KA, Speich B, et al. Albendazole and mebendazole administered alone or in combination with ivermectin against Trichuris trichiura/: a randomized controlled trial. Clin Infect Dis 2010;51(12):1420-8
   PubMed Web of Science ®Google Scholar
• Speich B, Ame SM, Ali SM, et al. Efficacy and safety of nitazoxanide, albendazole, and nitazoxanide-albendazole against Trichuris trichiura infection: a randomized controlled trial. PLoS Negl Trop Dis 2012;6(6):e1685
   PubMed Web of Science ®Google Scholar
• Caumes E, Carriere J, Datry A, et al. A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans. Am J Trop Med Hyg 1993;49(5):641-4
   PubMed Web of Science ®Google Scholar
• Pavli A, Maltezou HC. Leishmaniasis, an emerging infection in travelers. Int J Infect Dis 2010;14(12):e1032-9
   PubMed Web of Science ®Google Scholar
• Murray HW. Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg 2012;86(3):434-40
   PubMed Web of Science ®Google Scholar
• Tavares CAP, Fernandes AP, Melo MN. Molecular diagnosis of leishmaniasis. Expert Rev Mol Diagn 2003;3(5):657-67
   PubMed Web of Science ®Google Scholar
• Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005;366(9496):1561-77
   PubMed Web of Science ®Google Scholar
• Singh S. New developments in diagnosis of leishmaniasis. Indian J Med Res 2006;123(3):311-30
   PubMed Web of Science ®Google Scholar
• Bensoussan E, Nasereddin A, Jonas F, et al. Comparison of PCR assays for diagnosis of cutaneous leishmaniasis. J Clin Microbiol 2006;44(4):1435-9
   PubMed Web of Science ®Google Scholar
• Reveiz L, Maia-Elkhoury ANS, Nicholls RS, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update. Schallig HDFH, ed. PLoS One 2013;8(4):e61843
   PubMed Web of Science ®Google Scholar
• Arevalo J, Ramirez L, Adaui V, et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 2007;195(12):1846-51
   PubMed Web of Science ®Google Scholar
• Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006;19(1):111-26
   PubMed Web of Science ®Google Scholar
• Reithinger R, Dujardin J-C, Louzir H, et al. Cutaneous leishmaniasis. Lancet Infect Dis 2007;7(9):581-96
   PubMed Web of Science ®Google Scholar
• Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 2013;368(6):524-32
   PubMed Web of Science ®Google Scholar
• Kim DH, Chung HJ, Bleys J, Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 2009;3(2):e381
   PubMed Web of Science ®Google Scholar
• Shazad B, Abbaszadeh B, Khamesipour A. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur J Dermatol 2005;15(2):85-7
   PubMed Web of Science ®Google Scholar
• Sosa N, Capitan Z, Nieto J, et al. Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. Am J Trop Med Hyg 2013;89(3):557-63
   PubMed Web of Science ®Google Scholar
• Arevalo I, Tulliano G, Quispe A, et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007;44(12):1549-54
   PubMed Web of Science ®Google Scholar
• Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, et al. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 2005;40(10):1395-403
   PubMed Web of Science ®Google Scholar
• Firooz A, Khamesipour A, Ghoorchi MH, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol 2006;142(12):1575-9
   PubMed Web of Science ®Google Scholar
• Vasconcellos Ede CF, Pimentel MI, Schubach Ade O, et al. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000–2006). Am J Trop Med Hyg 2012;87(2):257-60
   PubMed Web of Science ®Google Scholar
• Soto J, Rojas E, Guzman M, et al. Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis. Clin Infect Dis 2013;56(9):1255-60
   PubMed Web of Science ®Google Scholar
• Blum J, Lockwood DNJ, Visser L, et al. Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. Int Health 2012;4(3):153-63
   PubMed Web of Science ®Google Scholar
• Mohebali M, Fotouhi A, Hooshmand B, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007;103(1):33-40
   PubMed Web of Science ®Google Scholar
• Rubiano LC, Miranda MC, Muvdi Arenas S, et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 2012;205(4):684-92
   PubMed Web of Science ®Google Scholar
• Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011;84(2):255-60
   PubMed Web of Science ®Google Scholar
• Machado PR, Ampuero J, Guimarães LH, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 2010;4(12):e912
   PubMed Web of Science ®Google Scholar
• Velez I, Lopez L, Sanchez X, et al. Efficacy of Miltefosine for the Treatment of American Cutaneous Leishmaniasis. Am J Trop Med Hyg 2010;83(2):351-6
   Web of Science ®Google Scholar
• Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004;38(9):1266-72
   PubMed Web of Science ®Google Scholar
• Solomon M, Pavlotzky F, Barzilai A, Schwartz E. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol 2013;68(2):284-9
   PubMed Web of Science ®Google Scholar
• Solomon M, Pavlotsky F, Leshem E, et al. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol 2011;25(8):973-7
   PubMed Web of Science ®Google Scholar
• Wortmann G, Zapor M, Ressner R, et al. Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2010;83(5):1028-33
   PubMed Web of Science ®Google Scholar
• Harms G, Scherbaum H, Reiter-Owona I, et al. Treatment of imported New World cutaneous leishmaniasis in Germany. Int J Dermatol 2011;50(11):1336-42
   PubMed Web of Science ®Google Scholar
• Morizot G, Kendjo E, Mouri O, et al. Travelers With Cutaneous Leishmaniasis Cured Without Systemic Therapy. Clin Infect Dis 2013;57(3):370-80
   PubMed Web of Science ®Google Scholar
• Sousa AQ, Frutuoso MS, Moraes EA, et al. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clin Infect Dis 2011;53(7):693-5
   PubMed Web of Science ®Google Scholar
• Emad M, Hayati F, Fallahzadeh MK, Namazi MR. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial. J Am Acad Dermatol 2011;64(3):606-8
   PubMed Web of Science ®Google Scholar
• Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002;346(12):891-5
   PubMed Web of Science ®Google Scholar
• Morizot G, Delgiudice P, Caumes E, et al. Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg 2007;76(1):48-52
   PubMed Web of Science ®Google Scholar
• Heukelbach J, Franck S, Feldmeier H. Therapy of tungiasis: a double-blinded randomized controlled trial with oral ivermectin. Mem Inst Oswaldo Cruz 2004;99(8):873-6
   PubMed Web of Science ®Google Scholar
• Ross AG, Vickers D, Olds GR, et al. Katayama syndrome. Lancet Infect Dis 2007;7(3):218-24
   PubMed Web of Science ®Google Scholar
• LaRocque RC, Deshpande BR, Rao SR, et al. Pre-travel health care of immigrants returning home to visit friends and relatives. Am J Trop Med Hyg 2013;88(2):376-80
   PubMed Web of Science ®Google Scholar
• Clark RL, Carter KC, Mullen AB, et al. Identification of the benzodiazepines as a new class of antileishmanial agent. Bioorg Med Chem Lett 2007;17(3):624-7
   PubMed Web of Science ®Google Scholar
• Serghides L, Kain KC. Peroxisome proliferator-activated receptor gamma-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNF-alpha secretion by monocytes/macrophages. J Immunol 2001;166(11):6742-8
   PubMed Web of Science ®Google Scholar
• Serghides L, Patel SN, Ayi K, et al. Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria. J Infect Dis 2009;199(10):1536-45
   PubMed Web of Science ®Google Scholar
• Boggild AK, Krudsood S, Patel SN, et al. Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2009;49(6):841-9
   PubMed Web of Science ®Google Scholar
• Eissa MM, Amer EI. Giardia lamblia: a new target for miltefosine. Int J Parasitol 2012;42(5):443-52
   PubMed Web of Science ®Google Scholar
• Eissa MM, El-Azzouni MZ, Amer EI, Baddour NM. Miltefosine, a promising novel agent for schistosomiasis mansoni. Int J Parasitol 2011;41(2):235-42
   PubMed Web of Science ®Google Scholar
• Debnath A, Parsonage D, Andrade RM, et al. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 2012;18(6):956-60
   PubMed Web of Science ®Google Scholar
• Tejman-Yarden N, Miyamoto Y, Leitsch D, et al. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob Agents Chemother 2013;57(5):2029-35
   PubMed Web of Science ®Google Scholar
• University of California, San Francisco. Amoebiasis Research. Center for Discovery and Innovation in Parasitic Diseases. Available from: /www.cdipd.org/index.php?option=com_content&view=article&id=69&Itemid=49&mid=3 [Last accessed 3 October 2013]
   Google Scholar
• Anthony J-P, Fyfe L, Smith H. Plant active components - a resource for antiparasitic agents? Trends Parasitol 2005;21(10):462-8
   PubMed Web of Science ®Google Scholar
• Force M, Sparks WS, Ronzio RA. Inhibition of enteric parasites by emulsified oil of oregano in vivo. Phytother Res 2000;14(3):213-14
   PubMed Web of Science ®Google Scholar
• Neafsey DE. Genome sequencing sheds light on emerging drug resistance in malaria parasites. Nat Genet 2013;45:589-90
   PubMed Web of Science ®Google Scholar
• The Medical Letter. Drugs for parasitic infections. 3rd edition. The Medical Letter, Inc; New York, NY: 2013
   Google Scholar
• González U, Pinart M, Rengifo-Pardo M, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009(2):CD004834
   PubMed Web of Science ®Google Scholar
• Monge-Maillo B, López-Vélez R. Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis. Drugs 2013;73(17):1889-920
   PubMed Web of Science ®Google Scholar
• Neves LO, Talhari AC, Gadelha EPN, et al. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An Bras Dermatol 2011;86(6):1092-101
   PubMed Web of Science ®Google Scholar
• González U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2008(4):CD005067
   PubMed Web of Science ®Google Scholar
• Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, et al. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 2005;72(2):133-7
   PubMed Web of Science ®Google Scholar
• Van der Meide WF, Sabajo LOA, Jensema AJ, et al. Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname. Int J Dermatol 2009;48(1):52-8
   PubMed Web of Science ®Google Scholar
• Lai A Fat EJSK, Vrede MA, Soetosenojo RM, Lai A Fat RFM. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol 2002;41(11):796-800
   PubMed Web of Science ®Google Scholar
• Hepburn NC, Tidman MJ, Hunter JA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1994;88(6):700-3
   PubMed Web of Science ®Google Scholar
• Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997;24(4):684-703
   PubMed Web of Science ®Google Scholar
• Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des 2002;8(4):319-42
   PubMed Web of Science ®Google Scholar
• Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001;65(5):466-70
   PubMed Web of Science ®Google Scholar
• Neva FA, Ponce C, Ponce E, et al. Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin. Trans R Soc Trop Med Hyg 1997;91(4):473-5
   PubMed Web of Science ®Google Scholar
• Amato VS, Tuon FF, Camargo RA, et al. Can we use a lower dose of liposomal amphotericin b for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 2011;85(5):818-19
   PubMed Web of Science ®Google Scholar